Načítá se...
Targeting mTOR in Glioblastoma: Rationale and Preclinical/Clinical Evidence
The mechanistic target of rapamycin (mTOR) drives several physiologic and pathologic cellular processes and is frequently deregulated in different types of tumors, including glioblastoma (GBM). Despite recent advancements in understanding the molecular mechanisms involved in GBM biology, the surviva...
Uloženo v:
| Vydáno v: | Dis Markers |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Hindawi
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6312595/ https://ncbi.nlm.nih.gov/pubmed/30662577 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2018/9230479 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|